A Proposal from the Montpellier World Health Organization Collaborating Centre for Better Management and Prevention of Anaphylaxis.

Adrenaline/epinephrine autoinjector Anaphylaxis Classification Epidemiology Management Prevention Treatment

Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
02 2021
Historique:
received: 30 06 2020
revised: 29 09 2020
accepted: 30 09 2020
pubmed: 16 10 2020
medline: 22 5 2021
entrez: 15 10 2020
Statut: ppublish

Résumé

Since the first description of anaphylaxis in 1902, its clinical importance as an emergency condition has been recognized worldwide. Anaphylaxis is a severe, potentially life-threatening systemic hypersensitivity reaction characterized by rapid onset and the potential to endanger life through respiratory or circulatory compromise. It is usually, although not always, associated with skin and mucosal changes. Although the academic/scientific communities have advocated to promote greater awareness and protocols for the management of anaphylaxis based on best evidence, there are few efforts documenting feedback as to the success of these efforts. In this article, we review the key unmet needs related to the diagnosis and management of anaphylaxis, and propose a public health initiative for prevention measures and a timetable action plan that intends to strengthen the collaboration among health professionals and especially primary care physicians dealing with anaphylaxis, which can encourage enhanced quality of care of patients with anaphylaxis. More than calling for a harmonized action for the best management of anaphylaxis to prevent undue morbidity and mortality, the Montpellier World Health Organization Collaborating Centre here proposes an action plan as a baseline for a global initiative against anaphylaxis. We strongly believe that these collaborative efforts are a strong public health and societal priority that is consistent with the overarching goals of providing optimal care of allergic patients and best practices of allergology.

Identifiants

pubmed: 33059097
pii: S2213-2198(20)31112-0
doi: 10.1016/j.jaip.2020.09.062
pii:
doi:

Substances chimiques

Epinephrine YKH834O4BH

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

676-683.e1

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Luciana Kase Tanno (LK)

Hospital Sírio-Libanês, São Paulo, Brazil; Division of Allergy, Department of Pulmonology, University Hospital of Montpellier, Montpellier, France; Sorbonne Université, INSERM UMR-S 1136, IPLESP, Equipe EPAR, Paris, France; WHO Collaborating Centre on Scientific Classification Support, Montpellier, France. Electronic address: luciana.tanno@gmail.com.

Nidhal Touati (N)

Division of Allergy, Department of Pulmonology, University Hospital of Montpellier, Montpellier, France.

Salome Allichon (S)

Division of Allergy, Department of Pulmonology, University Hospital of Montpellier, Montpellier, France.

Bryan Martin (B)

Medicine and Pediatrics, The Ohio State University, Columbus, Ohio.

Motohiro Ebisawa (M)

Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.

Ignacio Ansotegui (I)

Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia Erandio, Bilbao, Spain.

Mario Sanchez-Borges (M)

Allergy and Clinical Immunology Department, Centro Medico Docente La Trinidad, Caracas, Venezuela.

Victoria Cardona (V)

Allergy Section, Department of Internal medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain; ARADyAL Research Network, Madrid, Spain.

Paul A Greenberger (PA)

Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.

Dermot Ryan (D)

Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.

Guillaume Pouessel (G)

Department of Pediatrics, Children's Hospital, Roubaix, France; CHU Lille, Pediatric Pulmonology and Allergy Department, Lille University, Lille, France.

Etienne Beaudouin (E)

Regional Institute for Allergic and Environmental Disease Clinical Immunology, Metz Regional Hospital, Metz, France.

Jean-Marie Renaudin (JM)

Réseau d'Allergo-Vigilance (Allergy Vigilance Network), Vandoeuvre les Nancy, France.

Francis Thien (F)

Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia; Department of Respiratory Medicine, Eastern Health, Boxhill, VIC, Australia.

Yoon-Seok Chang (YS)

Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Ruby Pawankar (R)

Department of Pediatrics, Nippon Medical School, Tokyo, Japan.

Maximiliano Gomez (M)

Research & Education, Fundación Ayre, Allergy & Asthma Unit, Hospital San Bernardo, Catholic University of Salta, Salta, Argentina.

Edgardo Jares (E)

LIBRA Foundation and CMP, Buenos Aires, Argentina.

Patricia Latour Staffeld (PL)

Centro Avanzado de Alergia y Asma, Santo Domingo, Dominican Republic.

Ioana Agache (I)

Transylvania University, Brasov, Romania.

Antonella Muraro (A)

Food Allergy Referral Centre, Padua University Hospital, Padua, Italy.

Todd A Mahr (TA)

Pediatric Allergy and Clinical Immunology, Gundersen Health System, La Crosse, Wis.

James Sublett (J)

Section of Allergy & Immunology, Department of Pediatrics, University of Louisville School of Medicine, Louisville, Ky.

Thomas Casale (T)

Morsani College of Medicine, University of South Florida, Tampa, Fla.

David Lang (D)

Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.

Pascal Demoly (P)

Division of Allergy, Department of Pulmonology, University Hospital of Montpellier, Montpellier, France; Sorbonne Université, INSERM UMR-S 1136, IPLESP, Equipe EPAR, Paris, France; WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH